JP2022507741A5 - - Google Patents

Info

Publication number
JP2022507741A5
JP2022507741A5 JP2021527208A JP2021527208A JP2022507741A5 JP 2022507741 A5 JP2022507741 A5 JP 2022507741A5 JP 2021527208 A JP2021527208 A JP 2021527208A JP 2021527208 A JP2021527208 A JP 2021527208A JP 2022507741 A5 JP2022507741 A5 JP 2022507741A5
Authority
JP
Japan
Prior art keywords
antigen
seq
binding site
antibody
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021527208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507741A (ja
JP7271666B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062011 external-priority patent/WO2020106620A1/en
Publication of JP2022507741A publication Critical patent/JP2022507741A/ja
Publication of JP2022507741A5 publication Critical patent/JP2022507741A5/ja
Priority to JP2023072027A priority Critical patent/JP7587629B2/ja
Application granted granted Critical
Publication of JP7271666B2 publication Critical patent/JP7271666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021527208A 2018-11-19 2019-11-18 アンタゴニストcd40モノクローナル抗体およびその使用 Active JP7271666B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023072027A JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストcd40モノクローナル抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769514P 2018-11-19 2018-11-19
US62/769,514 2018-11-19
PCT/US2019/062011 WO2020106620A1 (en) 2018-11-19 2019-11-18 Antagonistic cd40 monoclonal antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023072027A Division JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストcd40モノクローナル抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2022507741A JP2022507741A (ja) 2022-01-18
JP2022507741A5 true JP2022507741A5 (cg-RX-API-DMAC7.html) 2022-11-01
JP7271666B2 JP7271666B2 (ja) 2023-05-11

Family

ID=68848451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021527208A Active JP7271666B2 (ja) 2018-11-19 2019-11-18 アンタゴニストcd40モノクローナル抗体およびその使用
JP2023072027A Active JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストcd40モノクローナル抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023072027A Active JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストcd40モノクローナル抗体およびその使用

Country Status (20)

Country Link
US (8) US11261258B2 (cg-RX-API-DMAC7.html)
EP (1) EP3883652A1 (cg-RX-API-DMAC7.html)
JP (2) JP7271666B2 (cg-RX-API-DMAC7.html)
KR (1) KR102627246B1 (cg-RX-API-DMAC7.html)
CN (2) CN113164781B (cg-RX-API-DMAC7.html)
AR (1) AR117091A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019385331B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009140A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120358C (cg-RX-API-DMAC7.html)
CL (1) CL2021001230A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007691A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191359A1 (cg-RX-API-DMAC7.html)
IL (1) IL283104B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005565A (cg-RX-API-DMAC7.html)
MY (1) MY204740A (cg-RX-API-DMAC7.html)
PE (1) PE20211293A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104776VA (cg-RX-API-DMAC7.html)
TW (1) TWI800694B (cg-RX-API-DMAC7.html)
WO (1) WO2020106620A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103353B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP2023539736A (ja) * 2020-08-25 2023-09-19 ブリストル-マイヤーズ スクイブ カンパニー 拮抗性cd40モノクローナル抗体で自己免疫性疾患を処置する方法
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
WO2023274007A1 (zh) * 2021-06-29 2023-01-05 舒泰神(北京)生物制药股份有限公司 特异性识别cd40的抗体及其应用
JP7833531B2 (ja) * 2021-07-14 2026-03-19 舒泰神(北京)生物製薬股フン有限公司 Cd40を特異的に認識する抗体およびその使用
WO2023186111A1 (zh) * 2022-04-02 2023-10-05 和铂医药(上海)有限责任公司 一种靶向cd40的抗原结合蛋白及其制备和应用
CN117264063B (zh) * 2023-03-22 2024-04-23 赛业(苏州)生物科技有限公司 一种抗gpc3抗体及其应用
CN119490596B (zh) * 2023-08-21 2026-01-23 菲鹏生物股份有限公司 一种抗人IgM抗体及其应用
KR20250116195A (ko) 2024-01-24 2025-08-01 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB2353887B (en) 1999-09-04 2003-09-24 Ibm Speech recognition system
WO2003028809A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Methods of therapy for b-cell malignancies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
PL1682177T3 (pl) * 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
PT1684805E (pt) * 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
AU2004287879C1 (en) * 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
RU2006141632A (ru) * 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
US20150315284A1 (en) 2004-11-09 2015-11-05 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
AU2006304387A1 (en) 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
CA2669412A1 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
US8629245B2 (en) 2007-05-01 2014-01-14 Research Development Foundation Immunoglobulin Fc libraries
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP2796467B1 (en) 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
US9303083B2 (en) 2010-10-04 2016-04-05 Riken Therapeutic agent for malignant tumors expressing MHC class II
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
NO2699601T3 (cg-RX-API-DMAC7.html) * 2011-04-21 2018-06-16
KR102037432B1 (ko) * 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
KR20250078601A (ko) 2011-09-30 2025-06-02 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
GB201308658D0 (en) 2013-05-14 2013-06-26 Isis Innovation Antibodies
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
EP3626740A1 (en) * 2014-08-14 2020-03-25 F. Hoffmann-La Roche AG Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
JP6518917B2 (ja) * 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗cd40抗体およびその使用
PE20180315A1 (es) * 2015-06-29 2018-02-09 Bristol Myers Squibb Co Anticuerpos para cd40
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
PE20181367A1 (es) 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
EP3523329A1 (en) 2016-10-06 2019-08-14 GlaxoSmithKline Intellectual Property Development Limited Antibodies with reduced binding to process impurities
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
US20200095323A1 (en) 2017-03-20 2020-03-26 The General Hospital Corporation MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
US20200148779A1 (en) 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
EP3704158A1 (en) 2017-11-03 2020-09-09 Novartis AG Anti-cd40 antibodies for use in treatment of sjögren's syndrome
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル-マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体

Similar Documents

Publication Publication Date Title
US11667722B2 (en) Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US20220267476A1 (en) Multispecific antibody constructs
US10851172B2 (en) Humanized antibodies against CD269 (BCMA)
KR102143506B1 (ko) 변형된 단백질 및 펩티드
JP6746564B2 (ja) Il−23a及びtnf−アルファを標的とする化合物ならびにその使用
RU2604196C2 (ru) Антитела против cd70
CN103946240B (zh) 对人ox40具有特异性的抗体分子
TWI280980B (en) Human antibodies that bind human IL-12 and methods for producing
ES2923143T3 (es) Anticuerpos monoclonales antagonistas contra CD40 y sus usos
CN103154029B (zh) 抗人tweak的抗体及其用途
JP2014513953A5 (cg-RX-API-DMAC7.html)
WO2015137843A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2022093640A (ja) 抗il-1治療に関する新しい適応症
JP2020509756A5 (cg-RX-API-DMAC7.html)
KR20170023212A (ko) 보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법
TW200831533A (en) Interleukin-13 binding proteins
JP2020521458A5 (cg-RX-API-DMAC7.html)
JP2014530611A5 (cg-RX-API-DMAC7.html)
JP2014511844A5 (cg-RX-API-DMAC7.html)
AU2023282504A1 (en) Igf1r antibodies
TW202540170A (zh) 抗原結合蛋白
TH2101002815A (th) โมโนโคลนอลแอนติบอดีที่เป็นแอนทาโกนิสท์ต่อ cd40 และการใช้แอนติบอดีดังกล่าว
NZ777121B2 (en) Antagonistic cd40 monoclonal antibodies and uses thereof
NZ777121A (en) Antagonistic cd40 monoclonal antibodies and uses thereof
WO2023025309A1 (zh) 一种cdc平台抗体